Cytokinetics Inc (CYTK)

Currency in USD
76.45
-1.04(-1.34%)
Closed·
76.67+0.22(+0.29%)
·

CYTK Earnings

Latest Release
Aug 06, 2026
EPS / Forecast
-1.50 / -1.63
Revenue / Forecast
28.6M / 17.09M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09--/-1.56--/28.15M----Free Sign Up
2026/06-1.50/-1.6328.60M/17.09M+7.98%+67.35%Free Sign Up
2026/03-1.67/-1.6519.35M/8.59M-1.21%+125.26%Free Sign Up
2025/12-1.50/-1.5617.76M/7.12M+3.85%+149.44%Free Sign Up
2025/09-2.55/-1.571.93M/6.05M-62.42%-68.1%Free Sign Up
2025/06-1.12/-1.4266.77M/2.01M+21.13%+3,221.89%Free Sign Up
2025/03-1.36/-1.371.60M/3.60M+0.73%-55.56%Free Sign Up
2024/12-1.26/-1.2216.93M/1.95M-3.28%+768.21%Free Sign Up
2024/09-1.36/-1.23463.00K/1.21M-10.57%-61.74%Free Sign Up
2024/06-1.31/-1.06249.00K/7.61M-23.58%-96.73%Free Sign Up

All numbers in USD

Cytokinetics Inc Earnings Call Summary for Q2/2026

  • Cytokinetics beat Q2 2026 estimates with loss of $1.50/share vs. $1.63 expected; revenue hit $28.6M, 67% above $17.09M forecast on MYQORZO strength.
  • MYQORZO generated $25.3M in net product revenue; over 1,500 patients dispensed by quarter-end, up from 400 in Q1, with June new-to-brand share topping 40%.
  • Company raised 2026 R&D and SG&A expense guidance to $860M-$890M from $830M-$870M to fund nHCM launch prep following positive ACACIA-HCM data.
  • Supplemental NDA filing for aficamten in nHCM expected Q4 2026; FDA reviewing MAPLE-HCM sNDA with PDUFA date Nov. 14, 2026 for obstructive HCM indication.
  • Cash position strengthened to $1.7B from $1.1B in Q1; European expansion underway with Germany launched, Netherlands approved, U.K. launch expected later 2026.
Last Updated: 2026-08-06, 06:22 p/m
Read Full Transcript

FAQ

What Is Cytokinetics Inc's Earnings Per Share (TTM)?

The Cytokinetics Inc EPS (TTM) is -7.18.

When Is The Next Cytokinetics Inc Earnings Date?

Cytokinetics Inc will release its next earnings report on Oct 29, 2026.

What Is Cytokinetics Inc’s Revenue Forecasts For Upcoming Quarters?

Cytokinetics Inc’s revenue forecast is 28.15M.

How Did Cytokinetics Inc React to the Company's Latest Earnings Report?

Cytokinetics Inc reported a +7.98% EPS surprise and a +67.35% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by -2.65%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.